Regeneron Pharmaceuticals Inc
REGN
View Detailed Chart
657.125USD
+4.215+0.65%
Market hours （ET）Quotes delayed by 15 min
69.92BMarket Cap
15.68P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.65%
5 Days
+12.38%
1 Month
+17.19%
6 Months
+15.51%
Year to Date
-7.75%
1 Year
-29.14%
View Detailed Chart
TradingKey Stock Score of Regeneron Pharmaceuticals Inc
Currency: USD Updated: 2025-10-29Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Regeneron Pharmaceuticals Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
28
analysts
Buy
Current Rating
758.876
Target Price
+15.95%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Regeneron Pharmaceuticals Inc Highlights
StrengthsRisks
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.67% year-on-year.
Undervalued
The company’s latest PE is 15.06, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 94.09M shares, decreasing 4.35% quarter-over-quarter.
Held by Mason Hawkins
Star Investor Mason Hawkins holds 160.58K shares of this stock.
Financial Indicators
EPS
No Data
Total revenue
No Data
Regeneron Pharmaceuticals Inc Info
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Ticker SymbolREGN
CompanyRegeneron Pharmaceuticals Inc
CEODr. Leonard S. Schleifer, M.D., Ph.D
Websitehttps://www.regeneron.com/
Related Instruments
+4.34%
+1.27%
+1.05%
+0.39%
+0.98%
-1.04%
-2.19%
-0.06%
+0.95%
+0.23%
+0.60%
+0.86%
+2.11%
+2.34%
+4.89%
+1.55%
-0.34%
-7.84%
+12.88%
-0.26%Popular Symbols
